Pipeline Drugs for Inflammation



Inflammation is the body's attempt at self-protection; the aim being to remove harmful stimuli, including damaged cells, irritants, or pathogens - and begin the healing process.

--heart disease, diabetes, Alzheimer's, stroke and cancer have in common? Scientists have linked each of these to a condition known as chronic inflammation,

Brodalumab is another possible market success for Amgen that is being developed in collaboration with AstraZeneca. The novel human monoclonal antibody binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 ligands to the receptor. By stopping IL-17 ligands from activating the receptor, brodalumab prevents the body from receiving signals that may result in inflammation. The IL-17 pathway plays a main role in inducing and promoting inflammatory disease processes.

IL-10 --Interleukin 10 (IL-10), also known as human cytokine synthesis inhibitory factor (CSIF), is an anti-inflammatory cytokine.

ABP 501 is Amgen's biosimilar drug designed to compete with AbbVie's anti-inflammatory drug Humira.


Celgene --Ozanimod is an experimental drug for the treatment of multiple sclerosis and ulcerative colitis.[1] It is an immunotherapy that modulates the sphingosine-1-phosphate 1 receptor -- big pipeline drug for Celgene.. bought Receptos for it.---The sphingosine-1-phosphate receptors regulate fundamental biological processes such as cell proliferation, angiogenesis, migration, cytoskeleton organization, endothelial cell chemotaxis, immune cell trafficking and mitogenesis. Sphingosine-1-phosphate receptors are also involved in immune-modulation and directly involved in suppression of innate immune responses from T cells.

Ozanimod is a small molecule sphingosine 1-phosphate 1 and 5 receptor modulator in development for immune-inflammatory indications including relapsing multiple sclerosis and inflammatory bowel disease. Treatment with S1P receptor modulators is believed to work by interfering with S1P signaling and blocks the response of lymphocytes (a type of white blood cell) to exit signals from the lymph nodes, sequestering them within the nodes. The result is thought to be a downward modulation of circulating lymphocytes and anti-inflammatory activity by inhibiting cell migration to sites of inflammation.